The pharmaceutical business is facing a big challenge: the high failure rate of medications in clinical trials. Traditional animal models frequently fail to precisely predict human responses, resulting in costly setbacks and delays. To solve this, groundbreaking technology is emerging: organs-on-chips. These microfluidic devices, which are meant to